Trials / Completed
CompletedNCT03387423
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
ESCALATE-RA A NON-INTERVENTIONAL STUDY OF CRITICAL FACTORS FOR ESCALATING DRUG TREATMENT IN PATIENTS TREATED WITH TOFACITINIB FOR MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,459 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This non-interventional study aims to identify key factors that are driving treatment decisions by rheumatologists in the treatment of rheumatoid arthritis (RA) patients starting treatment with Tofacitinib in a real world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib | Patients who are started on Tofacitinib treatment according to the drug label |
Timeline
- Start date
- 2017-11-02
- Primary completion
- 2023-07-17
- Completion
- 2023-07-17
- First posted
- 2018-01-02
- Last updated
- 2024-10-21
- Results posted
- 2024-10-21
Locations
91 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03387423. Inclusion in this directory is not an endorsement.